Vivoryon: still "too difficult pile"

Burning through tens of million in cash per year. Not easy to value possible future positive cash flows.

Saturday, December 17, 2022

Vivoryon: too difficult pile. Not for the Graham Defensive investor.

"Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimer’s disease (“AD”) drug development. The Company has demonstrated evidence of the disease modifying capabilities of its lead candidate varoglutamstat, currently in Phase 2 clinical studies in Europe and the U.S.. Underscoring the unique potential of varoglutamstat in mono- and combination therapy settings in AD, data generated to date show the potential for cognitive improvement and a beneficial safety profile at doses of high target engagement.

As previously announced, the Investors (including Claus Christiansen of Nordic Bioscience) agreed to invest an amount of EUR 15.0 million in the Company by purchasing 2,054,796 new ordinary shares at an offering price of EUR 7.30 per share by means of a capital increase from the Company." 

https://www.vivoryon.com/vivoryon-therapeutics-announcessuccessful-listing-of-2054796-shares/